News for Healthier Living
New Therapeutic Target Expands Options for Multiple Myeloma
In a Phase I clinical trial, the investigational bispecific antibody cevostamab reduced cancer in more than 40% of patients with multiple myeloma.
July 22, 2026
July 25 2026July 24 2026July 23 2026July 22 2026July 21 2026July 20 2026July 17 2026July 16 2026July 15 2026July 14 2026July 13 2026July 12 2026
|
|
|
|
|